Skip to content

Platelet-rich plasma versus estrogen therapy for treating genitourinary symptoms after menopause

Comparison of the Effectiveness of Platelet-Rich Plasma versus Estrogen Therapy on Vaginal Health Index and Female Sexual Function in Postmenopausal Women with Genitourinary Syndrome: A Parallel Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251103067867N1
Enrollment
20
Registered
2026-02-11
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal genitourinary syndrome.

Interventions

Intervention 1: Intervention group: Patients in this group use conjugated estrogen vaginal ointment (0.625 mg) for two months (every night in the first month, twice a week in the second month). Interv

Sponsors

Kurdistan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 45–65 years and sexually active Definitive diagnosis of genitourinary syndrome of menopause (GSM) based on clinical examination by a gynecologist and the standard Vaginal Health Index (VHI) checklist; patients with a score below 15 are eligible for the study At least one year since the last menstrual period Full informed consent to participate in the study No severe hormonal disorders No use of hormone therapy in the past 6 months Patients with contraindications to estrogen use (especially estrogen receptor–positive breast cancer, ovarian cancer, endometrial cancer, active thrombosis or history of thromboembolism, recent stroke or myocardial infarction, uncontrolled hypertension, advanced diabetes, or smoking) will be assigned to the platelet-rich plasma group

Exclusion criteria

Exclusion criteria: presence of inflammatory vaginal diseases Use of drugs affecting the reproductive system Presence of active genital infections Pregnancy and breastfeeding History of gynecological surgeries Use of corticosteroids

Design outcomes

Primary

MeasureTime frame
The mean Vaginal Health Index score based on vaginal pH status, assessment of epithelial integrity, vaginal moisture, vaginal elasticity, and the condition of vaginal discharge. Timepoint: Before the intervention, and at one month and three months after the intervention. Method of measurement: Vaginal Health Index (VHI) scoring checklist.;Average score of women's sexual performance. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: FSFI questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh Darvishi

Kurdistan University of Medical Sciences

lale.drv@gmail.com+98 87 3328 5910

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026